| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 1.1K | 6.2% | 0.6% |
| Total Income | 1.1K | 6.3% | 0.5% |
| Expenditure | 981.94 | 5.5% | 1.2% |
| PBT | 65.43 | 29.6% | 31.5% |
| Net Profit | 46.90 | 32.5% | 32.4% |
| OPM | 10.80% | 1.29pp | 7.58pp |
| NPM | 4.42% | 1.72pp | 2.09pp |
| EPS | 2.97 | 32.5% | 32.4% |
Jubilant Ingrevia Q3'FY26 Results: Revenue Up 3%, EBITDA Rises 8%, PAT Grows 8%
05 Feb 2026 · 5 Feb, 1:37 pm
Summary
Jubilant Ingrevia Limited has reported its Q3'FY26 results with a 3% increase in revenue, 8% growth in EBITDA, and an 8% rise in PAT. The company's Speciality Chemicals segment has driven growth, while the Nutrition business has maintained a healthy growth trajectory. The Chemical Intermediates segment has also sustained its market share with year-on-year volume growth.
Key Highlights
- 1
Speciality Chemicals segment fueling growth
- 2
Healthy trajectory of volume growth in Nutrition business
- 3
Chemical Intermediates segment maintaining market share
- 4
Sustained pricing pressure across all three segments
- 5
Double-digit volume growth leading to 3% revenue increase
- 6
8% EBITDA growth and 8% PAT growth
- 7
Interim dividend of 250% recommended
- 8
Steady recovery in volumes across the Chemicals Industry
- 9
Stable pharmaceutical end-use market with strength in Fine Chemicals portfolio
- 10
Steady recovery in Agrochemical sector
- 11
Strong Niacinamide demand in Nutrition market
- 12
Partial recovery in Acetyls portfolio expected in Q4 FY26
- 13
Commissioned a new boiler at Bharuch site
- 14
On track to commence delivery of a major CDMO order in Q4’FY26
- 15
Construction work begun on new multipurpose plant in Gajraula
Management Comments
Mr. Shyam S Bhartia
Chairman and Mr. Hari S Bhartia, Co- Chairman, Jubilant Ingrevia Limited
We are pleased to share the financial results for the third quarter and nine months of this fiscal year. On a year to date basis, our Speciality Chemicals segment has continued to fuel growth momentum, delivering revenue expansion and a robust double-digit increase in EBITDA. Our Nutrition business has sustained a healthy trajectory of volume growth across all core products. At the same time, our Chemical Intermediates segment has successfully maintained its market share while recording year on year volume growth. This quarter presented its challenges, with softer pricing across all three segments. However, strong volume growth helped offset this impact, resulting in overall business performance remaining stable.
Mr. Deepak Jain
Chief Executive Officer and Managing Director, Jubilant Ingrevia Limited
Over the past year, we have made significant progress across all pillars of our strategy, laying the groundwork for sustained long-term growth while ensuring stability in the near term, even amid current challenging global market conditions. These efforts are already delivering results, as reflected in our stable quarterly performance in our Specialty and Nutrition portfolio, overall margins, along with a substantially expanded pipeline of more than 100 new opportunities, including 16 wins this year.
Informational and educational content only. Not investment advice.